Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Diagnoplex SA and Unilabs Sign a Collaboration Agreement

Published: Thursday, September 19, 2013
Last Updated: Thursday, September 19, 2013
Bookmark and Share
Agreement to market the Colox® non-invasive colon cancer screening test.

Diagnoplex SA and Unilabs have signed a collaboration agreement to commercialize Colox®, a minimally invasive colorectal cancer assay within the Unilabs network.

The test will be available initially in the Swiss and Swedish markets.

The agreement combines Diagnoplex’s capacity to develop “high-return” molecular assays with Unilabs’ leading position in the European diagnostics market.

The agreement builds on a solid collaborative effort between the two companies and enables Unilabs to further differentiate itself through innovative molecular testing.

“This agreement opens a new and exciting chapter for Diagnoplex” said Stavros Therianos, founder and CEO of Diagnoplex SA. “We are able to enter into a strong collaboration with a European market leader such as Unilabs thanks to a patient- focused strategy for clinical product development. This collaboration demonstrates that a step-by-step approach, for the development of molecular screening tests, can effectively lead to the commercial availability of medically relevant diagnostics”.

Fernando de Górgolas, Unilabs Group Marketing & Business Development Director, said, “This collaboration with Diagnoplex is consistent with our strategy of launching innovative tests, that can bring a real benefit to patients and the healthcare community. Colox will strengthen the role of our molecular genetics laboratories in the diagnosis and monitoring of colorectal cancer.”

Thierry Mauvernay, Delegate of the Board of Debiopharm Group - a lead investor in Diagnoplex - agreed, adding “We are delighted that Diagnoplex has been able to establish this collaboration with an important actor in diagnostic market. We believe the Colox blood test has the potential to greatly increase the percentage of people that will be correctly screened for colorectal cancer”.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
FNIH Launches Project to Evaluate Biomarkers in Cancer Patients
Company has announced that it has launched a new project to evaluate the effectiveness of liquid biopsies as biomarkers in colorectal cancer patients.
Drugs that May Combat Deadly Antibiotic-Resistant Bacteria Uncovered
Study identifies 79 compounds that inhibit carbapenem-resistant Enterobacteriaceae (CRE).
Making Precision Medicine a Reality
Researchers are one step closer to understanding the genetic and biological basis of diseases like cancer, diabetes, Alzheimer’s and rheumatoid arthritis – and identifying new drug targets and therapies.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!